Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 17, 2026 · Filed Mar 20, 2026
A board member of Corcept Therapeutics paid $813K out of pocket for Corcept Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$812,836
Shares × reported transaction price
$500K–$1M
+2.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
21 days after results of Feb 24, 2026, 44 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +8.6% | −2.2% | +10.8% |
| 30 days | +33.8% | +9.3% | +24.5% |
| 90 days | +130.7% | +15.1% | +115.5% |
| 180 days | +222.8% | +16.3% | +206.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$819K of Corcept Therapeutics
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.